Abstract
Many patients with breast cancer develop brain metastases, which are typically treated through whole-brain irradiation. As a potential alternative treatment, targeted radionuclide therapy (TRT) could be delivered early, targeting the areas of the vasculature where tumor cells are penetrating into the brain. We have developed a Monte Carlo model representing brain vasculature to evaluate and understand a variety of potential therapeutic nuclides: (alpha emitters) Pb-212, At-211, Ac-225, Bi-213, and Tb-149; (beta/Auger electron emitters) Lu-177, Tb-161, I-124, In-111, Y-90, Zr-89, and Ga-67. The micron-scale dose distributions from all radioactive decay products were modeled in Geant4, as well as eV-scale interactions through the G4DNA models [1] . These interactions were then superimposed on an atomic-scale DNA model [2] to estimate strand break yields. Some of the alpha emitters have decay chains with multiple daughter nuclei; we investigate the change in dose profiles and biological effectiveness as a function of time. Alpha emitters have higher doses per decay, and the depth-dose profiles fall off less quickly. The general qualities of the depth-dose profiles are maintained through biologically-relevant variations in vasculature geometry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
